ARG70756

Human IL35 recombinant protein (His-tagged, C-ter)

Human IL35 recombinant protein (His-tagged, C-ter) for SDS-PAGE

Overview

Product Description CHO expressed, His-tagged (C-ter) Human IL35 recombinant protein
Tested Application SDS-PAGE
Target Name IL35
Species Human
A.A. Sequence Ala23 - Pro228 Arg23 - Ala215
Expression System CHO
Alternate Names CLMF; Cytotoxic lymphocyte maturation factor 35 kDa subunit; NFSK; NK cell stimulatory factor chain 1; CLMF p35; NKSF1; IL-12 subunit p35; IL-12A; Interleukin-12 subunit alpha; P35

Properties

Form Powder
Purification Note Endotoxin level is less than 0.1 EU/µg of the protein, as determined by the LAL test.
Purity > 85% (by SDS-PAGE)
Buffer PBS (pH 7.4)
Reconstitution It is recommended to reconstitute the lyophilized protein in sterile water to a concentration not less than 200 μg/mL and incubate the stock solution for at least 20 min at room temperature to make sure the protein is dissolved completely.
Storage Instruction For long term, lyophilized protein should be stored at -20°C or -80°C. After reconstitution, aliquot and store at -20°C or -80°C for up to one month. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening.
Note For laboratory research only, not for drug, diagnostic or other use.

Bioinformation

Gene Symbol IL12A
Gene Full Name interleukin 12A
Background Interleukin 35 (IL-35) is an IL-12 family cytokine produced by regulatory, but not effector, T-cells and plays a role in immune suppression. It is a dimeric protein composed of IL-12α and IL-27β chains, which are encoded by two separate genes called IL12A and EBI3, respectively. Secreted by regulatory T-cells (Tregs), IL-35 suppresses inflammatory responses of immune cells. IL-35 is not constitutively expressed in tissues, but the gene encoding IL-35 is transcribed by vascular endothelial cells, smooth muscle cells and monocytes after activation with proinflammatory stimuli. Studies in mice show the absence of either IL-35 chain from regulatory Tregs reduces the cells' ability to suppress inflammation; this has been observed during cell culture experiments and using an experimental model for inflammatory bowel disease. To produce its suppressive effects (eg on collagen-induced arthritis), IL-35 has selective activities on different T-cell subsets; it induces proliferation of Treg cell populations but reduces activity of Th17 cell populations. [provided by wikipedia 2016]